Subscribe to Newsletter

Business Practice

Discovery & Development Business Practice

Design and formulation of nanomedicines

In this white paper the specific mechanisms by which nanoparticles are designed and formulated for therapeutic purposes and in which NTA has had a significant part to play is discussed.

Discovery & Development Biosimilars

Taylor Dispersion Analysis explained

Taylor Dispersion Analysis is an ultra-low volume, microcapillary flow technique for sizing and stability of biomolecules in complex solutions, and offers advantages for orthogonal and complementary biophysical characterization measurements.

Discovery & Development Business Practice

Accelerate liquid formulation development for protein biopharmaceuticals

The work presented here illustrates how Differential Scanning Calorimetry (DSC) is used in the early stages of protein characterization to rapidly provide critical data about protein stability that can be used as a guide to support and accelerate liquid formulation.

Discovery & Development Business Practice

Reverse engineering of a pharmaceutical formulation

The Morphologi G3-ID can be used to generate component-specific particle size and shape data required to aid the reverse engineering of solid oral dose formulations. Here, we provide an example case study for a powder formulation.

Discovery & Development Business Practice

Thinking Inside – and Outside – the Box

Sitting Down With... Diane Paskiet, Director of Scientific Affairs at West Pharmaceutical Services, USA.

Business & Regulation Business Practice

The Adverse Event Data Advantage

A personal experience led us to examine how adverse drug events data can be used to benefit the industry.

Business & Regulation Business Practice

The CMO Serialization Threat

The serialization deadlines are coming. It may seem an age away, but preparing for serialization is not as straightforward as you may think. Do you really want to get left behind?

Business & Regulation Business Practice

All Eyes on EMA Approvals

From anti-cancer viruses to H3 blocking narcolepsy drugs – we present a year in European drug approvals

Business & Regulation Business Practice

Cross-Country Cancer Cost Comparison

Oncology medication prices can vary significantly between countries – but by how much and why?

Business & Regulation Business Practice

An Issue of Quality

| Stephanie Vine

2015 has been a difficult year for Indian pharma companies – and ASSOCHAM is calling for the country to get its “house in order”.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register